Dogwood Therapeutics (DWTX) Operating Expenses (2020 - 2026)

Dogwood Therapeutics has reported Operating Expenses for 7 years, with the latest figure at $14.1 million in Q2 2026.

• On a quarterly basis, Operating Expenses rose 258.48% year-over-year to $14.1 million in Q2 2026; TTM through Jun 2026 was $38.8 million, a 112.98% increase from a year earlier, with the FY2025 full-year figure at $28.0 million, up 128.74% from the prior year.
• Operating Expenses was $14.1 million for Q2 2026 at Dogwood Therapeutics, up from $5.1 million in the prior quarter.
• The five-year high for Operating Expenses was $15.8 million in Q3 2025, with the low at $1.1 million in Q2 2024.
• Average Operating Expenses over 5 years is $4.3 million, with a median of $3.1 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2025: Operating Expenses tumbled 60.69% in 2023, then surged 587.0% in 2025.
• Over 5 years, Operating Expenses stood at $2.1 million in 2022, then tumbled by 45.54% to $1.1 million in 2023, then soared by 562.68% to $7.5 million in 2024, then sank by 49.53% to $3.8 million in 2025, then jumped by 269.48% to $14.1 million in 2026.
• The last three Operating Expenses figures came in at $14.1 million (Q2 2026), $5.1 million (Q1 2026), and $3.8 million (Q4 2025), per Business Quant data.